230 related articles for article (PubMed ID: 27737606)
1. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Hsiue EH; Lee JH; Lin CC; Yang JC
Expert Rev Mol Diagn; 2016 Dec; 16(12):1251-1257. PubMed ID: 27737606
[TBL] [Abstract][Full Text] [Related]
2. therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Syed YY
Mol Diagn Ther; 2016 Apr; 20(2):191-8. PubMed ID: 26891729
[TBL] [Abstract][Full Text] [Related]
3. Analytical performance of the cobas EGFR mutation assay for Japanese non-small-cell lung cancer.
Kimura H; Ohira T; Uchida O; Matsubayashi J; Shimizu S; Nagao T; Ikeda N; Nishio K
Lung Cancer; 2014 Mar; 83(3):329-33. PubMed ID: 24439568
[TBL] [Abstract][Full Text] [Related]
4. Comparison study of the performance of the QIAGEN EGFR RGQ and EGFR pyro assays for mutation analysis in non-small cell lung cancer.
Cushman-Vokoun AM; Crowley AM; Rapp SA; Greiner TC
Am J Clin Pathol; 2013 Jul; 140(1):7-19. PubMed ID: 23765529
[TBL] [Abstract][Full Text] [Related]
5. Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction.
Oskina N; Oscorbin I; Khrapov E; Boyarskikh U; Subbotin D; Demidova I; Imyanitov E; Filipenko M
Mol Diagn Ther; 2017 Oct; 21(5):555-562. PubMed ID: 28589341
[TBL] [Abstract][Full Text] [Related]
6. A novel, rapid point-of-care test for lung cancer patients to detect epidermal growth factor receptor gene mutations by using real-time droplet-PCR and fresh liquid cytology specimens.
Asaka S; Yoshizawa A; Matsuda K; Yamaguchi A; Yamamoto H; Shiina T; Nakata R; Ogawa K; Zhang M; Honda T
Oncol Rep; 2017 Feb; 37(2):1020-1026. PubMed ID: 27922678
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Kazandjian D; Blumenthal GM; Yuan W; He K; Keegan P; Pazdur R
Clin Cancer Res; 2016 Mar; 22(6):1307-12. PubMed ID: 26980062
[TBL] [Abstract][Full Text] [Related]
8. Efficiency of the Therascreen® RGQ PCR kit for the detection of EGFR mutations in non-small cell lung carcinomas.
Vallée A; Le Loupp AG; Denis MG
Clin Chim Acta; 2014 Feb; 429():8-11. PubMed ID: 24269715
[TBL] [Abstract][Full Text] [Related]
9. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S; González Á; Cunquero Tomas AJ; Calabuig Fariñas S; Ferrero M; Mirda D; Sirera R; Jantus-Lewintre E; Camps C
Expert Rev Mol Diagn; 2020 Jun; 20(6):575-582. PubMed ID: 32011193
[TBL] [Abstract][Full Text] [Related]
10. Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Riely GJ; Pao W; Pham D; Li AR; Rizvi N; Venkatraman ES; Zakowski MF; Kris MG; Ladanyi M; Miller VA
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):839-44. PubMed ID: 16467097
[TBL] [Abstract][Full Text] [Related]
11. Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Kimura H; Kasahara K; Kawaishi M; Kunitoh H; Tamura T; Holloway B; Nishio K
Clin Cancer Res; 2006 Jul; 12(13):3915-21. PubMed ID: 16818687
[TBL] [Abstract][Full Text] [Related]
12. EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Kimura H; Fujiwara Y; Sone T; Kunitoh H; Tamura T; Kasahara K; Nishio K
Br J Cancer; 2006 Nov; 95(10):1390-5. PubMed ID: 17060940
[TBL] [Abstract][Full Text] [Related]
13. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.
Malapelle U; Sirera R; Jantus-Lewintre E; Reclusa P; Calabuig-Fariñas S; Blasco A; Pisapia P; Rolfo C; Camps C
Expert Rev Mol Diagn; 2017 Mar; 17(3):209-215. PubMed ID: 28129709
[TBL] [Abstract][Full Text] [Related]
14. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Sasaki S; Yoshioka Y; Ko R; Katsura Y; Namba Y; Shukuya T; Kido K; Iwakami S; Tominaga S; Takahashi K
Respir Investig; 2016 Jan; 54(1):14-9. PubMed ID: 26718140
[TBL] [Abstract][Full Text] [Related]
16. Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
He C; Zheng L; Xu Y; Liu M; Li Y; Xu J
Clin Chim Acta; 2013 Oct; 425():119-24. PubMed ID: 23886554
[TBL] [Abstract][Full Text] [Related]
17. Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Jackman DM; Yeap BY; Sequist LV; Lindeman N; Holmes AJ; Joshi VA; Bell DW; Huberman MS; Halmos B; Rabin MS; Haber DA; Lynch TJ; Meyerson M; Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(13):3908-14. PubMed ID: 16818686
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutations in 510 Finnish non--small-cell lung cancer patients.
Mäki-Nevala S; Rönty M; Morel M; Gomez M; Dawson Z; Sarhadi VK; Telaranta-Keerie A; Knuuttila A; Knuutila S
J Thorac Oncol; 2014 Jun; 9(6):886-91. PubMed ID: 24828666
[TBL] [Abstract][Full Text] [Related]
19. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T
J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005
[TBL] [Abstract][Full Text] [Related]
20. First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Wu JY; Yu CJ; Yang CH; Wu SG; Chiu YH; Gow CH; Chang YC; Hsu YC; Wei PF; Shih JY; Yang PC
Am J Respir Crit Care Med; 2008 Oct; 178(8):847-53. PubMed ID: 18583573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
